In silico docking and molecular dynamics simulation of 3-dehydroquinate synthase (DHQS) from Mycobacterium tuberculosis

• Published in: Journal of molecular modeling 2018-06, Vol.24 (6), p.132-12, Article 132
• Main Authors: Isa, Mustafa Alhaji, Majumdhar, Rita Singh, Haider, Shazia
• Format: Article
• Language: English
• Subjects: Binding energy; Binding sites; Biocompatibility; Biosynthesis; Characterization and Evaluation of Materials; Chemistry; Chemistry and Materials Science; Computer Appl. in Life Sciences; Computer Applications in Chemistry; Excretion; Ligands; Metabolism; Molecular chains; Molecular docking; Molecular dynamics; Molecular Medicine; Original Paper; Simulation; Theoretical and Computational Chemistry; Toxicity; Tuberculosis
• ISSN: 1610-2940; 0948-5023
• DOI: 10.1007/s00894-018-3637-4

The shikimate pathway is as an attractive target because it is present in bacteria, algae, fungi, and plants but does not occur in mammals. In Mycobacterium tuberculosis (MTB), the shikimate pathway is integral to the biosynthesis of naphthoquinones, menaquinones, and mycobactin. In these study, novel inhibitors of 3-dehydroquinate synthase (DHQS), an enzyme that catalyzes the second step of the shikimate pathway in MTB, were determined. 12,165 compounds were selected from two public databases through virtual screening and molecular docking analysis using PyRx 8.0 and Autodock 4.2, respectively. A total of 18 compounds with the best binding energies (−13.23 to −8.22 kcal/mol) were then selected and screened for absorption, distribution, metabolism, excretion, and toxicity (ADMET) analysis, and nine of those compounds were found to satisfy all of the ADME and toxicity criteria. Among those nine, the three compounds—ZINC633887 (binding energy = −10.29 kcal/mol), ZINC08983432 (−9.34 kcal/mol), and PubChem73393 (−8.61 kcal/mol)—with the best binding energies were further selected for molecular dynamics (MD) simulation analysis. The results of the 50-ns MD simulations showed that the two compounds ZINC633887 and PubChem73393 formed stable complexes with DHQS and that the structures of those two ligands remained largely unchanged at the ligand-binding site during the simulations. These two compounds identified through docking and MD simulation are potential candidates for the treatment of TB, and should undergo validation in vivo and in vitro.